Logo image of LYRA

LYRA THERAPEUTICS INC (LYRA) Stock Fundamental Analysis

NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD

18.42  -5.86 (-24.14%)

After market: 18.7 +0.28 (+1.52%)

Fundamental Rating

3

Overall LYRA gets a fundamental rating of 3 out of 10. We evaluated LYRA against 195 industry peers in the Pharmaceuticals industry. While LYRA has a great health rating, there are worries on its profitability. While showing a medium growth rate, LYRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LYRA has reported negative net income.
LYRA had a negative operating cash flow in the past year.
In the past 5 years LYRA always reported negative net income.
LYRA had a negative operating cash flow in each of the past 5 years.
LYRA Yearly Net Income VS EBIT VS OCF VS FCFLYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of LYRA (-141.22%) is worse than 83.08% of its industry peers.
LYRA has a worse Return On Equity (-2053.98%) than 83.08% of its industry peers.
Industry RankSector Rank
ROA -141.22%
ROE -2053.98%
ROIC N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
LYRA Yearly ROA, ROE, ROICLYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

LYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYRA Yearly Profit, Operating, Gross MarginsLYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

LYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LYRA has more shares outstanding
Compared to 5 years ago, LYRA has more shares outstanding
There is no outstanding debt for LYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LYRA Yearly Shares OutstandingLYRA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
LYRA Yearly Total Debt VS Total AssetsLYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

LYRA has an Altman-Z score of 5.99. This indicates that LYRA is financially healthy and has little risk of bankruptcy at the moment.
LYRA has a Altman-Z score of 5.99. This is amongst the best in the industry. LYRA outperforms 82.05% of its industry peers.
LYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.99
ROIC/WACCN/A
WACC10.15%
LYRA Yearly LT Debt VS Equity VS FCFLYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

LYRA has a Current Ratio of 2.96. This indicates that LYRA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LYRA (2.96) is comparable to the rest of the industry.
LYRA has a Quick Ratio of 2.96. This indicates that LYRA is financially healthy and has no problem in meeting its short term obligations.
LYRA's Quick ratio of 2.96 is in line compared to the rest of the industry. LYRA outperforms 56.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
LYRA Yearly Current Assets VS Current LiabilitesLYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

LYRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.45%.
The Revenue for LYRA has decreased by -29.38% in the past year. This is quite bad
The Revenue has been growing by 74.24% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-3.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.71%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-65.6%

3.2 Future

The Earnings Per Share is expected to grow by 14.89% on average over the next years. This is quite good.
The Revenue is expected to grow by 134.91% on average over the next years. This is a very strong growth
EPS Next Y59.88%
EPS Next 2Y23.57%
EPS Next 3Y14.85%
EPS Next 5Y14.89%
Revenue Next Year-24.65%
Revenue Next 2Y223.19%
Revenue Next 3Y157.48%
Revenue Next 5Y134.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYRA Yearly Revenue VS EstimatesLYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
LYRA Yearly EPS VS EstimatesLYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LYRA. In the last year negative earnings were reported.
Also next year LYRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYRA Price Earnings VS Forward Price EarningsLYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYRA Per share dataLYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as LYRA's earnings are expected to grow with 14.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.57%
EPS Next 3Y14.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LYRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYRA THERAPEUTICS INC

NASDAQ:LYRA (6/9/2025, 4:34:52 PM)

After market: 18.7 +0.28 (+1.52%)

18.42

-5.86 (-24.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners31.66%
Inst Owner Change-5.41%
Ins Owners3.08%
Ins Owner Change48.15%
Market Cap1.22B
Analysts48.89
Price TargetN/A
Short Float %N/A
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.4%
Min EPS beat(2)-30.72%
Max EPS beat(2)13.92%
EPS beat(4)2
Avg EPS beat(4)-28.85%
Min EPS beat(4)-121.19%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)-9.02%
EPS beat(12)7
Avg EPS beat(12)-6.89%
EPS beat(16)8
Avg EPS beat(16)-7.79%
Revenue beat(2)0
Avg Revenue beat(2)-14.35%
Min Revenue beat(2)-25.25%
Max Revenue beat(2)-3.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.34%
Min Revenue beat(4)-40.26%
Max Revenue beat(4)67.6%
Revenue beat(8)4
Avg Revenue beat(8)28.96%
Revenue beat(12)6
Avg Revenue beat(12)32.2%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4542.86%
EPS NQ rev (3m)-6090.48%
EPS NY rev (1m)-3833.57%
EPS NY rev (3m)-3961.37%
Revenue NQ rev (1m)21.76%
Revenue NQ rev (3m)180.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)17.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1030.12
P/FCF N/A
P/OCF N/A
P/B 315.26
P/tB 315.26
EV/EBITDA N/A
EPS(TTM)-60
EYN/A
EPS(NY)-33.83
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.02
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -141.22%
ROE -2053.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z 5.99
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)295.99%
Cap/Depr(5y)601.39%
Cap/Sales(3y)77.13%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.71%
EPS Next Y59.88%
EPS Next 2Y23.57%
EPS Next 3Y14.85%
EPS Next 5Y14.89%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-65.6%
Revenue Next Year-24.65%
Revenue Next 2Y223.19%
Revenue Next 3Y157.48%
Revenue Next 5Y134.91%
EBIT growth 1Y37.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.16%
OCF growth 3YN/A
OCF growth 5YN/A